New York-based healthcare funding agency OrbiMed has invested a complete of $85 million in Swiss firm vVARDIS, recognized for its drill-free therapy for early tooth decay, the businesses stated in a latest assertion.
OrbiMed introduced the closing of a $50 million funding spherical, including to an preliminary $35 million funding made in February 2025.
“After our preliminary funding, we’ve seen firsthand the momentum vVARDIS is constructing within the dental market with its Curodont™ merchandise,” stated Matthew Rizzo, normal associate at OrbiMed. He added that Curodont is “gaining actual traction.”
Provided in 10% of U.S. dental clinics
Drs. Haley and Goly Abivardi, founders and co-CEOs of vVARDIS, stated Curodont is now provided in almost 10 per cent of U.S. dental workplaces.
Moreover, a couple of million enamel have been handled with Curodont in the US since January 2024, and over 400,000 sufferers have obtained therapy thus far this 12 months, in line with their press launch.
“That’s why we’re excited to deepen our dedication and broaden our funding to assist vVARDIS in its subsequent part of development,” Rizzo stated.
FDA-approved since 2019
Curodont obtained CE marking approval to be used within the European Union and Switzerland in 2012. It entered numerous worldwide markets beginning in 2016 and obtained U.S. Meals and Drug Administration clearance in 2019, permitting its industrial availability in the US.
Younger Improvements, producer and distributor of dental provides and gear, primarily based in Algonquin, Illinois., started distributing Curodont Restore Fluoride Plus in 2021.
In September 2024, Henry Schein introduced it’s now the unique distributor within the U.S. for Curodont Restore Fluoride Plus, a non-invasive preventive therapy for early-stage cavities.
Learn associated article: Henry Schein turns into unique U.S. distributor for non-Invasive cavity therapy Curodont
